BioWorld

Jan. 6, 2006

Nuvelo Surges On Alfimeprase Agreement For Up To $385M

Nuvelo Inc.'s stock benefitted Thursday when the company entered a collaboration with pharmaceutical giant Bayer HealthCare AG to develop and commercialize the cardiovascular drug alfimeprase. (BioWorld Today) Read More

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

AVEO In-Licenses Kinase Inhibitor From Mitsubishi

NeoPharm Raising $35.7M; Pivotal Phase III Goes On

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Appointments And Advancements

Other News To Note

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...